Mock-ups and specimens
The European Medicines Agency operates a checking process of the printed materials used in the packaging and labelling of centrally authorised medicines.
The aim of this checking process is to improve the quality of the printed materials that patients and healthcare workers receive with a medicine. This includes the outer and inner packaging of the medicine, and the printed package leaflet.
The Agency reviews mock-ups and specimens of the packaging and labelling of medicines authorised via the centralised procedure, both before the medicine is marketed and following certain changes to the medicine's authorisation:
- Mock-ups are copies of the flat artwork design in full colour, presented so that, following cutting and folding where necessary, it provides a replica of both the outer and immediate packaging so that the three
dimensional presentation of the label text is clear. - Specimens are samples of the actual printed outer and immediate packaging materials and package leaflet, i.e. the 'sales presentation'.
-
List item
Checking process of mock-ups and specimens of outer / immediate labelling and package leaflets of human medicinal products in the centralised procedure (PDF/283.39 KB)
First published: 22/01/2007
Last updated: 28/09/2022
EMA/305821/2006 Rev. 4 -
List item
Mock-ups and specimens: Response form (DOC/487.5 KB)
First published: 05/04/2013
Last updated: 05/04/2013 -
List item
Specimen submission form (DOCX/28.35 KB)
First published: 25/11/2008
Last updated: 28/09/2022 -
List item
Standard operating procedure for checking of mock-ups and specimens for new applications and extensions (PDF/108.9 KB)
Adopted
First published: 21/10/2008
Last updated: 20/12/2010
Legal effective date: 17/12/2010
SOP/H/3013 -
List item
Standard operating procedure for checking of mock-ups and specimens for renewals (PDF/94.06 KB)
Adopted
First published: 10/06/2008
Last updated: 20/12/2010
Legal effective date: 17/12/2010
SOP/H/3217 -
List item
Standard operating procedure for checking of mock-ups and specimens for transfer of marketing authorisation (PDF/85.45 KB)
Adopted
First published: 10/06/2008
Last updated: 20/12/2010
Legal effective date: 17/12/2010
SOP/H/3218 -
List item
Standard operating procedure for checking of mock-ups and specimens for all post-authorisation procedures other than new applications, line extensions, renewals and transfers (PDF/85.6 KB)
Adopted
First published: 10/06/2008
Last updated: 20/12/2010
Legal effective date: 17/12/2010
SOP/H/3219
The QRD group has agreed on a contact point list for any request to place the unique identifier, as required by the Falsified Medicines Directive, via a sticker. Applicants/MAHs should contact directly Member States who will then communicate their decision to the requester as well as inform EMA of the outcome.
Related information: Commission Delegated Regulation (EU) 2016/161 and Safety features for medicinal products for human use questions and answers (Q.2.21).